SCHEMBL30346424

SCHEMBL30346424

CCO[C@H]1CC[C@@H](Nc2ncc3c(-c4ccc5nc(C)sc5c4)c[nH]c3n2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 1/20 0.37
▸ BRD4 O60885 2/20 0.36
▸ RET P07949 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ MAPK8 P45983 3/20 0.36
▸ MAPK9 P45984 3/20 0.36
▸ MAPK10 P53779 3/20 0.36
▸ CCNK O75909 3/20 0.35
▸ CDK7 P50613 3/20 0.35
▸ CCNH P51946 3/20 0.35
▸ MNAT1 P51948 3/20 0.35
▸ CDK12 Q9NYV4 3/20 0.35
▸ RIPK2 O43353 1/20 0.35
▸ DYRK2 Q92630 3/20 0.34
▸ CLK2 P49760 1/20 0.34
▸ CLK3 P49761 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25215129 1.00 ROCK2 (0.37) ROCK2BRD4RETABL1MAPK8
SCHEMBL25215131 1.00 ROCK2 (0.37) ROCK2BRD4RETABL1MAPK8
SCHEMBL25266090 0.91 RET (0.45) ROCK2BRD4RETABL1MAPK8
SCHEMBL25203199 0.91 RET (0.45) ROCK2BRD4RETABL1MAPK8
SCHEMBL30348307 0.88 CCNK (0.38) ROCK2BRD4RETABL1CCNK
SCHEMBL25207829 0.88 CCNK (0.38) ROCK2BRD4RETABL1CCNK
SCHEMBL25158434 0.87 CDC7 (0.42) ROCK2BRD4RETABL1MAPK9
SCHEMBL25158420 0.86 DYRK1A (0.44) ROCK2BRD4RETABL1MAPK8
SCHEMBL30348489 0.86 DYRK1A (0.44) ROCK2BRD4RETABL1MAPK8
SCHEMBL25204277 0.85 ROCK2 (0.37) ROCK2BRD4RETABL1CCNK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 ROCK2 998/4885BRD4 1417/4885RET 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback